Patients with advanced non–small cell lung cancer (NSCLC) whose tumors harbor anaplastic lymphoma kinase (ALK) gene fusions benefit from treatment with ALK inhibitors (ALKi). Analysis of cell-free circulating tumor DNA (cfDNA) may provide a noninvasive way to identify ALKfusions and actionable resistance mechanisms without an invasive biopsy.
Related Authors
Benjamin Philip Levy, MD
Clinical Director of Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital
Facebook
Twitter
YouTube
BROADCASTMED